Yange Tian Selected Research

Bu-Fei-Yi-Shen

1/2022	Effective-Component Compatibility of Bufei Yishen Formula III Combined with Electroacupuncture Suppresses Inflammatory Response in Rats with Chronic Obstructive Pulmonary Disease via Regulating SIRT1/NF-κB Signaling.
11/2021	Effective-component compatibility of Bufei Yishen formula protects COPD rats against PM2.5-induced oxidative stress via miR-155/FOXO3a pathway.
11/2021	[Compatibility characteristics of Bufei Yishen formula III in regulating chronic obstructive pulmonary disease mucus hypersecretion].
11/2021	Effective-components combination improves airway remodeling in COPD rats by suppressing M2 macrophage polarization via the inhibition of mTORC2 activity.
3/2021	A chinese herbal formula ameliorates COPD by inhibiting the inflammatory response via downregulation of p65, JNK, and p38.
1/2021	Identification of Potential Key Genes in the Pathogenesis of Chronic Obstructive Pulmonary Disease Through Bioinformatics Analysis.
7/2020	Effective-component compatibility of Bufei Yishen formula II inhibits mucus hypersecretion of chronic obstructive pulmonary disease rats by regulating EGFR/PI3K/mTOR signaling.
1/2020	Bufei Yishen Formula Restores Th17/Treg Balance and Attenuates Chronic Obstructive Pulmonary Disease via Activation of the Adenosine 2a Receptor.
1/2019	Effect of Bufei Yishen Granules Combined with Electroacupuncture in Rats with Chronic Obstructive Pulmonary Disease via the Regulation of TLR-4/NF-κB Signaling.
5/2018	Restoring Th17/Treg balance via modulation of STAT3 and STAT5 activation contributes to the amelioration of chronic obstructive pulmonary disease by Bufei Yishen formula.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yange Tian Research Topics

Disease

33	Chronic Obstructive Pulmonary Disease (COPD) 02/2022 - 01/2014
11	Bacterial Infections (Bacterial Infection) 01/2022 - 01/2015
8	Inflammation (Inflammations) 01/2022 - 01/2017
2	Airway Remodeling 02/2022 - 11/2021
2	Mitochondrial Diseases (Mitochondrial Disease) 01/2019 - 03/2015
2	Hypertrophy 01/2016 - 01/2015
1	Vascular Remodeling 01/2022
1	Hypoxia (Hypoxemia) 11/2021
1	Wounds and Injuries (Trauma) 11/2021
1	Pathologic Constriction (Stenosis) 01/2020
1	Lung Injury 01/2020
1	Pulmonary Fibrosis (Fibrosing Alveolitis) 01/2018

Drug/Important Bio-Agent (IBA)

18	Bu-Fei-Yi-ShenIBA 01/2022 - 01/2014
15	SmokeIBA 01/2022 - 01/2015
10	Proteins (Proteins, Gene)FDA Link 01/2022 - 03/2015
9	CytokinesIBA 11/2021 - 01/2015
7	bufei jianpiIBA 01/2022 - 01/2015
6	Therapeutic UsesIBA 01/2022 - 01/2014
5	Messenger RNA (mRNA)IBA 01/2022 - 01/2019
5	CollagenIBA 11/2021 - 01/2016
4	InterleukinsIBA 01/2022 - 01/2014
4	NF-kappa B (NF-kB)IBA 01/2022 - 01/2019
4	Aminophylline (Carine)FDA LinkGeneric 01/2019 - 03/2015
4	AntioxidantsIBA 06/2017 - 01/2016
3	Pharmaceutical PreparationsIBA 11/2021 - 01/2014
3	Peptide Hydrolases (Proteases)FDA Link 07/2020 - 01/2016
3	Matrix Metalloproteinases (MMPs)IBA 01/2019 - 01/2015
3	Oxidoreductases (Dehydrogenase)IBA 06/2017 - 01/2016
2	Mechanistic Target of Rapamycin Complex 2IBA 02/2022 - 11/2021
2	MicroRNAs (MicroRNA)IBA 11/2021 - 01/2019
2	Particulate MatterIBA 11/2021 - 01/2020
2	p38 Mitogen-Activated Protein KinasesIBA 03/2021 - 01/2017
2	paeonolIBA 01/2021 - 07/2020
2	nobiletinIBA 01/2021 - 07/2020
2	icariinIBA 01/2021 - 07/2020
2	Biomarkers (Surrogate Marker)IBA 01/2019 - 02/2015
2	Arachidonic Acid (Vitamin F)IBA 06/2017 - 01/2015
2	Protease Inhibitors (Protease Inhibitor)IBA 01/2017 - 01/2016
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2022
1	Interleukin-10 (Interleukin 10)IBA 01/2022
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2022
1	LipopolysaccharidesIBA 01/2022
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022
1	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2022
1	Proto-Oncogene Proteins c-akt (Protein Kinase B)IBA 01/2022
1	Sirtuin 1IBA 01/2022
1	TOR Serine-Threonine KinasesIBA 01/2022
1	salicylhydroxamic acid (SHAM)IBA 01/2022
1	quxieIBA 11/2021
1	Phosphotransferases (Kinase)IBA 03/2021
1	Biological ProductsIBA 01/2021
1	ginsenoside Rh1IBA 01/2021
1	Plant ExtractsIBA 01/2021
1	Cytokine Receptors (Cytokine Receptor)IBA 01/2021
1	Interleukin-17 (Interleukin 17)IBA 01/2021
1	Mitogen-Activated Protein KinasesIBA 01/2021
1	astragaloside AIBA 07/2020
1	GinsenosidesIBA 07/2020
1	Adenosine (Adenocard)FDA LinkGeneric 01/2020
1	Adenosine Monophosphate (AMP)IBA 01/2020
1	Interleukin-4 (Interleukin 4)IBA 01/2020
1	Protein Kinases (Protein Kinase)IBA 01/2020
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2020
1	Caspase 3 (Caspase-3)IBA 01/2019
1	Adenosine Triphosphate (ATP)IBA 01/2019
1	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2019
1	Saline SolutionIBA 01/2019
1	Interleukin-6 (Interleukin 6)IBA 01/2019
1	Fatty Acids (Saturated Fatty Acids)IBA 06/2017
1	Linoleic Acid (Linoleate)IBA 06/2017
1	ProteomeIBA 06/2017
1	LipidsIBA 06/2017
1	alpha-Linolenic Acid (Linolenic Acid)IBA 06/2017
1	JNK Mitogen-Activated Protein KinasesIBA 01/2017
1	Pulmonary Surfactant-Associated Protein D (Surfactant Protein D)IBA 01/2016
1	Pulmonary Surfactants (Pulmonary Surfactant)IBA 01/2016
1	Myosins (Myosin)IBA 01/2014

Therapy/Procedure

10	Therapeutics 01/2022 - 01/2014
7	Chinese Traditional Medicine (Traditional Chinese Medicine) 01/2022 - 01/2015
3	Electroacupuncture 01/2022 - 01/2019
3	Acupuncture Points (Acupuncture Point) 01/2017 - 08/2015
1	Activities of Daily Living (ADL) 01/2020
1	Oral Administration 01/2017